US EditionPublished • loading... • Updated
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Insilico will use its AI platform to accelerate oncology drug discovery while Servier leads clinical and commercial efforts in a deal valued at $888 million.
- On Jan. 4, 2026, Insilico Medicine announced a multi-year R&D collaboration with Servier in Cambridge valued up to US$888 million, with Insilico leading AI-driven discovery and Servier sharing costs and leading commercialization.
- Leveraging its Pharma AI platform, Insilico Medicine targets challenging oncology targets by designing new drug molecules from genomics and biological data rather than screening libraries.
- Nominated from 2021 to 2024, Insilico Medicine says it nominated 20 preclinical candidates with timelines of 12 to 18 months and synthesized 60 to 200 molecules per program, while ISM6331 and ISM3412 are in global Phase I trials and four oncology programs are out-licensed.
- Under the deal terms, Insilico Medicine is eligible for up to US$32 million in upfront and near-term R&D payments, following its HK$2.28 billion IPO days earlier.
- The deal positions Insilico Medicine as a leader in AI-driven drug discovery, with Christophe Thurieau and Alex Zhavoronkov calling it an endorsement of Insilico's AI platform and R&D expertise.
Insights by Ground AI
59 Articles
59 Articles
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery
·New York, United States
Read Full Article
Insilico, newly listed in Hong Kong, strikes up to $888M oncology deal with Servier
Days after going public on the Hong Kong Stock Exchange, Insilico Medicine has struck a multi-year oncology drug discovery partnership with France’s Servier worth up to $888 million. The collaboration will focus on developing oncology therapies, by combining Insilico’s AI-driven drug discovery platforms with Servier’s global expertise in cancer drug development. Insilico pointed to its… The post Insilico, newly listed in Hong Kong, strikes up t…
Coverage Details
Total News Sources59
Leaning Left5Leaning Right5Center19Last UpdatedBias Distribution66% Center
Bias Distribution
- 66% of the sources are Center
66% Center
L 17%
C 66%
R 17%
Factuality
To view factuality data please Upgrade to Premium
